Skip to main content
hello world

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Eplontersen continued to show improvement in ATTRv-PN through 85 weeks

PR Newswire - Mon Jul 10, 2023

CARLSBAD, Calif., July 10, 2023  /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced positive topline, 85-week data from the Phase 3 NEURO-TTRansform study in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).  Ionis and AstraZeneca's eplontersen continued to show sustained improvements in measures of neuropathy disease and a favorable safety and tolerability profile.

Read more at prnewswire.com